We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image

DESMOID TUMORS MARKET ANALYSIS

Desmoid Tumors Market, By Drug Type (Non-steroidal anti-inflammatory drugs(NSAIDs), Targeted Therapy, Chemotherapy, Hormone Therapy, Others), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Retail Pharmacies), and By Geography (Asia-Pacific , North America, Europe, South America, Middle East & Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

  • Published In : Dec 2022
  • Code : CMI5449
  • Pages :457
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Desmoid Tumors MarketSize and Trends

Global desmoid tumors market is estimated to be valued at US$ 2,494.1 million in 2022 and is expected to exhibit a CAGR of 7.3% during the forecast period (2022-2030).

Figure 1.Global Desmoid Tumors Market Share (%), by Drug Type, 2022

Global Desmoid Tumors Market - Drivers

Robust pipeline of novel drugs for treatment of desmoid tumors is expected to drive market growth over the forecast period. For instance, in June 2022, Iterion Therapeutics, a venture-backed clinical-stage biotechnology company exploring innovative cancer therapeutics, announced that findings from a Phase 1 study of tegavivint in patients with desmoid tumors would be highlighted in a poster presentation and discussion session at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO 2022), a meeting for conducting scientific events for oncology professionals, patient advocates, industry representatives, and major media outlets worldwide.

Increase in the technological advancements in desmoid tumor treatment is expected to drive market growth over the forecast period. For instance, in June 2021, Profound Medical, a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced that its Sonalleve Magnetic Resonance-guided High Intensity Focused Ultrasound (MR-HIFU) system had received the Conformité Européenne (CE) mark for the treatment of desmoid tumors. Traditional treatment options include radiofrequency ablation and surgery, which carry unique risks for patients. Sonalleve combines real-time MR imaging and thermometry with thermal ultrasound to enable precise, noninvasive ablation of diseased tissue. The treatment offers desmoid tumor patients with a treatment that can be performed safely with clinical improvement without the risks of invasive procedures, surgery, ionizing radiation exposure, or anesthesia. MR-HIFU offers a valuable treatment option for the often difficult to treat desmoid tumors. The potential benefits of MR-HIFU treatment is thought to outweigh the risks for patients, as MR-HIFU treatment can be repeated in case of recurrent disease with limited side-effects in contrary to the conventional treatment methods.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.